PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Status:
Not yet recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab
govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as
pathologic complete response (pCR) rates, in the perioperative setting in patients with
Muscle Invasive Bladder Cancer (MIBC) who are either unfit for platinum-based chemotherapy or
unwilling to receive that therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Fundación para el Progreso de la Oncología en Cantabria